BioTuesdays

Tag - BTIG

SQZ-Biotech-Logo
Markets

Analysts start SQZ Biotechnologies at buy

Analysts with Stifel and BTIG launched coverage of SQZ Biotechnologies (NYSE:SQZ) with “buy” ratings and price targets of $38 and $40, respectively. The stock closed at $27.62 on Nov. 23. “We believe SQZ’s Cell Squeeze...

November 24, 2020
Biodesix Logo
Markets

Analysts start Biodesix at buy and OP

Analysts for Canaccord Genuity, BTIG and William Blair launched coverage of Biodesix (NASDAQ:BDSX) with “buy” and “outperform” ratings. Shares of Biodesix closed at $17.09 on Nov. 20. Canaccord analyst Max Masucci...

November 23, 2020
Silence-Therapeutics-Logo
Markets

BTIG starts Silence Therapeutics at buy; PT $32

BTIG initiated coverage of Silence Therapeutics (NASDAQ, AIM: SLN) with a “buy” rating and $32 price target. The stock closed at $16.70 on Nov. 17. The company is a development stage therapeutics company based on nearly...

November 18, 2020
Progenity-Logo
Markets

BTIG starts Progenity at buy; PT $12

BTIG initiated coverage of Progenity (NASDAQ:PROG) with a “buy” rating and price target of $12. The stock closed at $7.80 on Oct. 22. Progenity is one of the top providers of non-invasive prenatal testing (NIPT) and...

October 23, 2020
Zosano Logo
Markets

BTIG cuts Zosano Pharma PT to $2 from $7

BTIG slashed the price target for Zosano Pharma (NASDAQ:ZSAN) to $2 from $7, citing a complete response letter about the NDA for Qtrypta, a transdermal microneedle system form of zolmitriptan in development for acute...

October 22, 2020
Vericel Logo
Markets

BTIG ups Vericel PT to $30 from $23

BTIG raised its price target for Vericel (NASDAQ:VCEL) to $30 from $23 after an analyst and investor event focused primarily on NexoBrid, a recently licensed burn enzymatic debridement product from MediWound. ...

October 19, 2020
Aldeyra-Therapeutics
Markets

BTIG starts Aldeyra Therapeutics at buy; PT $29

BTIG initiated coverage of Aldeyra Therapeutics (NASDAQ:ALDX) with a “buy” rating and $29 price target. The stock closed at $6.86 on Oct. 15. Aldeyra is targeting reactive aldehyde species (RASP) for a range of...

October 16, 2020
Neuronetics Logo
Markets

BTIG ups Neuronetics PT to $10 from $6

BTIG raised its price target for Neuronetics (NASDAQ:STIM) to $10 from $6, citing takeaways from recent virtual investor meetings, which focused on how the company’s new CEO, Keith Sullivan, will be reshaping the...

October 6, 2020
89bio
Markets

BTIG starts 89bio at buy; PT $51

BTIG launched coverage of 89bio (NASDAQ:ETNB) with a “buy” rating and $51 price target. The stock closed at $33.14 on July 22. 89bio is developing BIO89-100, a stabilized fibroblast growth factor 21 (FGF21) analog, for...

July 23, 2020
Endologix Logo
Markets

BTIG cuts Endologix to neutral; removes price target

BTIG downgraded Endologix (NASDAQ:ELGX) to “neutral” without a price target, citing “greater uncertainty” that the potential COVID-19 impact on revenue could put the company’s financial covenants in peril. The stock...

May 12, 2020